JP2015514742A - β−アミロイドにより誘発された毒性と関連する疾患の治療における、３−（１’−アダマンチル）−１−アミノメチル−３，４−ジヒドロ−５，６−ジヒドロキシ−１Ｈ−２−ベンゾピランの使用 - Google Patents

β−アミロイドにより誘発された毒性と関連する疾患の治療における、３−（１’−アダマンチル）−１−アミノメチル−３，４−ジヒドロ−５，６−ジヒドロキシ−１Ｈ−２−ベンゾピランの使用 Download PDF

Info

Publication number
JP2015514742A
JP2015514742A JP2015506307A JP2015506307A JP2015514742A JP 2015514742 A JP2015514742 A JP 2015514742A JP 2015506307 A JP2015506307 A JP 2015506307A JP 2015506307 A JP2015506307 A JP 2015506307A JP 2015514742 A JP2015514742 A JP 2015514742A
Authority
JP
Japan
Prior art keywords
amyloid
compound
disease
toxicity
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015506307A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514742A5 (enExample
Inventor
カーン，ファリド
ドイグ，アンドルー・ジェイムズ
モーダク，スワナンダ・アール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manchester
Original Assignee
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manchester filed Critical University of Manchester
Publication of JP2015514742A publication Critical patent/JP2015514742A/ja
Publication of JP2015514742A5 publication Critical patent/JP2015514742A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015506307A 2012-04-20 2013-04-18 β−アミロイドにより誘発された毒性と関連する疾患の治療における、３−（１’−アダマンチル）−１−アミノメチル−３，４−ジヒドロ−５，６−ジヒドロキシ−１Ｈ−２−ベンゾピランの使用 Pending JP2015514742A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1206984.5 2012-04-20
GBGB1206984.5A GB201206984D0 (en) 2012-04-20 2012-04-20 New therapeutic use
PCT/GB2013/050985 WO2013156782A1 (en) 2012-04-20 2013-04-18 3- (1' -adamantyl) - 1 - aminomethyl - 3, 4 - dihydro - 5, 6 - dihydroxy - 1h - 2 - benzopyran for use in the treatment of a disease associated with beta-amyloid induced toxicity

Publications (2)

Publication Number Publication Date
JP2015514742A true JP2015514742A (ja) 2015-05-21
JP2015514742A5 JP2015514742A5 (enExample) 2016-06-16

Family

ID=46261631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015506307A Pending JP2015514742A (ja) 2012-04-20 2013-04-18 β−アミロイドにより誘発された毒性と関連する疾患の治療における、３−（１’−アダマンチル）−１−アミノメチル−３，４−ジヒドロ−５，６−ジヒドロキシ−１Ｈ−２−ベンゾピランの使用

Country Status (5)

Country Link
US (1) US20150133537A1 (enExample)
EP (1) EP2844244A1 (enExample)
JP (1) JP2015514742A (enExample)
GB (1) GB201206984D0 (enExample)
WO (1) WO2013156782A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104644658A (zh) * 2013-11-22 2015-05-27 富力 人参皂苷Rg3在制备用于预防或/和治疗痴呆病症药物中的应用及药物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10298135A (ja) * 1997-04-10 1998-11-10 Pfizer Inc フルオロ置換アダマンタン誘導体
WO2004103263A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10298135A (ja) * 1997-04-10 1998-11-10 Pfizer Inc フルオロ置換アダマンタン誘導体
WO2004103263A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF PHARMACOLGY, vol. 260, no. 1, JPN6017001335, 1994, pages 85 - 87, ISSN: 0003483229 *
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 283, no. 1, JPN6017001334, 1997, pages 183 - 189, ISSN: 0003483228 *

Also Published As

Publication number Publication date
EP2844244A1 (en) 2015-03-11
GB201206984D0 (en) 2012-06-06
US20150133537A1 (en) 2015-05-14
WO2013156782A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
AU2011291506B2 (en) Methods of treating mild cognitive impairment (mci) and related disorders
US11046650B2 (en) Deuterated compounds and uses thereof
Leboyer et al. Brief report: A double-blind study of naltrexone in infantile autism
CN105744932A (zh) 用于治疗神经障碍的包含托拉塞米和巴氯芬的组合物
EP3022206B1 (en) Epha4 inhibitors as neuroprotective agents
WO2012027548A1 (en) Compounds and methods for prevention and treatment of alzheimer's and other diseases
Cosden et al. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy
Dai et al. Activation of liver X receptor α protects amyloid β1–40 induced inflammatory and senescent responses in human retinal pigment epithelial cells
EP2814491A1 (en) Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions
JP6353110B2 (ja) タウ凝集阻害剤
KR101915016B1 (ko) 자가포식 향상물질 및 그 용도
KR20210102208A (ko) 신경계 질환의 치료
JP2015514742A (ja) β−アミロイドにより誘発された毒性と関連する疾患の治療における、３−（１’−アダマンチル）−１−アミノメチル−３，４−ジヒドロ−５，６−ジヒドロキシ−１Ｈ−２−ベンゾピランの使用
JP2021512925A (ja) ドーパミン前駆体
KR20220071285A (ko) 미토콘드리아 기능 향상 및 미토콘드리아 질환 치료를 위한 화합물의 신규 치료적 용도
Fehr et al. Anle138b mitigates post-hypoxic cognitive impairment, α-Synuclein aggregation and UPR activation in Drosophila melanogaster
Márcio Vasconcelos Batista-Filho et al. Role of methylene blue in trauma neuroprotection and neuropsychiatric diseases
WO2025095099A1 (ja) 前頭側頭葉変性症治療剤及び治療用組成物
WO2025221864A1 (en) Compositions and methods for restoring cognitive and behavioral function
HK40060568A (en) Domperidone antineurodegenerative combinations and use
KR20200086563A (ko) 산화적 스트레스로부터 성상세포를 보호하는 조성물
US20220000854A1 (en) Domperidone antineurodegenerative combinations and use
Tripathi et al. Neurodegenerative Disease and Treatments

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170912